This week, several of my colleagues and I are at AdvaMed’s annual MedTech Conference where we are discussing a wide range of topics, including value-based contracting, cybersecurity, and digital health. Earlier today, I led a panel focused on the decline of early-stage investment in medtech, and its impact on startup activity. During the session, we dove into how dwindling investments in those early phases could put future innovation at risk. We also discussed potential strategies for attracting new medtech investors.
Pedro Arboleda | Deloitte Consulting LLP
Pedro Arboleda is a Managing Director in the strategy practice of Deloitte Monitor/Deloitte Consulting LLP. He focuses on developing commercial and business development strategies for small/mid-cap and $15Bil+ corporations. He is passionate about the convergence of health, predictive data analytics, cognitive technologies, behavioral science, and companies offering novel solutions that transform business models and tackle challenging societal health issues.
Recent Posts
Can new investors help medtech refill the new product pipeline?
Posted by
Pedro Arboleda | Deloitte Consulting LLP on September 27, 2017